TRI Automates Clinical Trial Risk Oversight with OPRA 26.2

The core of the update, the AI agent RiskIQ, scans uploaded protocols to generate a draft assessment of Critical-to-Quality factors and associated risks. Rather than automating decisions, the system requires human intervention; risk managers must review, edit, or reject AI suggestions before they move into live study environments. This ensures that every risk assessment remains grounded in organizational standards while maintaining a complete, exportable audit trail.

Beyond initial assessment, the platform shifts risk management into an active monitoring phase. By linking risks to specific centralized controls, users receive alerts when performance metrics deviate from established tolerances. The integration eliminates the need for external spreadsheets, allowing cross-functional teams to collaborate on reviews within a single interface. These review processes, including safety and eligibility checks, now feature detailed change logs to help medical monitors demonstrate compliance more effectively. The update is available as of October 14, 2026, marking another step in TRI’s long-standing effort to standardize risk-based quality management across global clinical trials.